1
|
Amuti S, Saito Y, Fukuyoshi S, Miyake K, Newman DJ, O’Keefe BR, Lee KH, Nakagawa-Goto K. Unusual Vilasinin-Class Limonoids from Trichilia rubescens. Molecules 2024; 29:651. [PMID: 38338394 PMCID: PMC10856392 DOI: 10.3390/molecules29030651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 01/17/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024] Open
Abstract
Eight vilasinin-class limonoids, including the unusually chlorinated rubescins K-M (1-3), the 2,3-epoxylated rubescin N (4), and rubescins O-R (5-8), were newly isolated from Trichilia rubescens. The structures of the isolated compounds were determined through spectroscopic and spectrometric analyses, as well as ECD calculations. The natural occurrence of chlorinated limonoids 1-3 was confirmed by chemical methods and HPLC analysis of a roughly fractionated portion of the plant extract. Eight selected limonoids, including previously known and new compounds, were evaluated for antiproliferative activity against five human tumor cell lines. All tested limonoids, except 8, exhibited significant potency, with IC50 values of <10 μM; in particular, limonoid 14 strongly inhibited tumor cell growth, with IC50 values of 0.54-2.06 μM against all tumor cell lines, including multi-drug-resistant cells.
Collapse
Affiliation(s)
- Saidanxia Amuti
- School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan; (S.A.); (Y.S.); (S.F.)
| | - Yohei Saito
- School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan; (S.A.); (Y.S.); (S.F.)
| | - Shuichi Fukuyoshi
- School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan; (S.A.); (Y.S.); (S.F.)
| | - Katsunori Miyake
- School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji 192-0392, Japan;
| | - David J. Newman
- Natural Products Branch, Developmental Therapeutics Program, Center of Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702-1201, USA; (D.J.N.); (B.R.O.)
| | - Barry R. O’Keefe
- Natural Products Branch, Developmental Therapeutics Program, Center of Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702-1201, USA; (D.J.N.); (B.R.O.)
- Molecular Targets Program, Center for Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702-1201, USA
| | - Kuo-Hsiung Lee
- Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7568, USA
- Chinese Medicine Research and Development Center, China Medical University and Hospital, 2 Yuh-Der Road, Taichung 40447, Taiwan
| | - Kyoko Nakagawa-Goto
- School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan; (S.A.); (Y.S.); (S.F.)
- Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7568, USA
| |
Collapse
|